Maa: Kanada
Kieli: englanti
Lähde: Health Canada
ROCURONIUM BROMIDE
AURO PHARMA INC
M03AC09
ROCURONIUM BROMIDE
10MG
SOLUTION
ROCURONIUM BROMIDE 10MG
INTRAVENOUS
15G/50G
Prescription
NEUROMUSCULAR BLOCKING AGENTS
Active ingredient group (AIG) number: 0126317001; AHFS:
APPROVED
2020-05-07
Page 1 of 35 PRODUCT MONOGRAPH PR ROCURONIUM BROMIDE INJECTION 10 mg/mL Solution for Injection (50 mg/5 mL and 100 mg/10 mL) Sterile Solution Non-depolarizing Skeletal Neuromuscular Blocking Agent AURO PHARMA INC. Date of Preparation: 3700 Steeles Avenue West, Suite # 402 May 5, 2020 Woodbridge, Ontario, L4L 8K8, Canada Submission Control No: 213553 Page 2 of 35 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ............................................................ 3 SUMMARY PRODUCT INFORMATION ................................................................................. 3 INDICATIONS AND CLINICAL USE ....................................................................................... 3 CONTRAINDICATIONS........................................................................................................... 4 WARNINGS AND PRECAUTIONS .......................................................................................... 4 ADVERSE REACTIONS ........................................................................................................... 8 DRUG INTERACTIONS.......................................................................................................... 11 DOSAGE AND ADMINISTRATION ....................................................................................... 12 OVERDOSAGE ....................................................................................................................... 18 ACTION AND CLINICAL PHARMACOLOGY ...................................................................... 18 STORAGE AND STABILITY .................................................................................................. 25 SPECIAL HANDLING INSTRUCTIONS................................................................................. 26 DOSAGE FORMS, COMPOSITION AND PACKAGING ........................................................ 26 PART II: SCIENTIFIC INFORMATION................................................................................. 27 PHARMACEUTICAL INFO Lue koko asiakirja